News & Views | Telix Pharmaceuticals Limited

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

Telix is pleased to announce that a first patient has been dosed in a Phase II study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with triple-negative breast cancer (TNBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France.

Second Industry Body Updates Guidance for Use of PSMA PET Imaging

Telix welcomes the Society of Nuclear Medicine and Molecular Imaging (SNMMI) updated Appropriate Use Criteria (AUC) for prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging.

NCCN Guidelines Updated to Include PSMA-PET Imaging

Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes PSMA PET imaging modalities, including Ga-68 PSMA-11.

FDA Approves Phase II Kidney Cancer Therapy Study

Telix announces the FDA has accepted the IND Application to undertake a clinical study of Telix’s investigational kidney cancer therapy, TLX250.

Japanese Prostate Cancer Imaging Study Completes Enrolment

Telix has completed a Phase I clinical trial of TLX591-CDx for prostate cancer imaging in Japan in collaboration with Kanazawa University.

Telix and Lightpoint Medical to Collaborate on Radioguided Surgery

Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI® in radioguided surgery (RGS)

Telix and Merck to Commence Pan-Cancer Clinical Combination Studies

Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany.

Two New Studies to Explore Telix Assets in Breast Cancer Theranostics

Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx in breast cancer.

Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®

Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being investigated in lung and ovarian cancers

Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia

Telix announces Phase II academic study of TLX66 in children with high-risk leukemia.